An observational study in Heart Failure, CAD - Coronary Artery Disease and CABG, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Recruiting at 1 site in Russia. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.
Among the 25 studies in Heart Failure with a site in Russia, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, and was the 23rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:
Pyatigorsk City Clinical Hospital Number 1 · Sites in Russia
Ages 18+
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Meshalkin Research Institute of Pathology of Circulation · Sites in Russia
Ages 18–75
I.M. Sechenov First Moscow State Medical University · Sites in Russia
Ages 18+
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 18–60 · Men only · Healthy volunteers
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 66 across the 15 interventional studies, 250 across the 10 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
Tomsk National Research Medical Center of the Russian Academy of Sciences is the lead sponsor of 73 studies on the registry; 19 are open to participants now.
Tomsk National Research Medical Center of the Russian Academy of Sciences has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Failure with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770349Tomsk National Research Medical Center of the Russian Academy of SciencesUltrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure | 2026-11 |
| NCT07375433National Medical Research Center for Therapy and Preventive MedicineHeart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis | 2026-12-31 |
| NCT07480915Tomsk National Research Medical Center of the Russian Academy of SciencesRisk Stratification of MACE in Heart Failure Patients Who Undergoing CABG | 2027-03 |
| NCT07372196Meshalkin Research Institute of Pathology of CirculationLeft Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy | 2027-05-01 |
| NCT07552142I.M. Sechenov First Moscow State Medical UniversityPatient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 25 studies in Heart Failure with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).
The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.
The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.
PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).
The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.
The study will include patients with a documented diagnosis of CHF and CAD who are recommended for coronary artery bypass grafting by the cardiac team.
The study will collect and record patient examination and treatment data, which will be conducted in accordance with established standards of care for patients with CAD and will not be part of the study.
The study will also analyze GDF-15. At each study center, upon patient enrollment, after signing informed consent, blood will be collected from the cubital vein in the morning before CABG. The blood will be collected in a vacuum tube containing 8 ml of clot activator (red-topped vacutainer) containing clot activator. Further preparation of the blood samples for analysis will include centrifugation for 10 minutes at 2,500 rpm, separation of the serum using a pipette into three 500 μg Eppendorf tubes, and freezing at -20°C. Serum samples will be transported by a specialized cold chain company. Analysis will be performed after a single thaw of the serum/plasma in the laboratory of the Cardiology Research Institute of Tomsk National Research Medical Center.
The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.
At each study center, patients with CHF and ischemic heart disease will be assessed for inclusion and exclusion criteria when deciding on the need for CABG and whether the patient consents to the procedure. The principal investigator is expected to ensure that all patients meeting the inclusion and exclusion criteria are consistently enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Time to first adverse cardiovascular event (months)
Time to first adverse cardiovascular event, including cardiovascular (CV) death or nonfatal myocardial infarction (MI) and/or nonfatal stroke and/or unplanned revascularization and/or heart failure (HF) hospitalization and/or worsening of heart failure (worsening by at least one NYHA class requiring increased intensity of diuretic therapy).
Time frame: From enrollment to the end of treatment at 12 months
Deaths from cardiovascular causes (percentage)
Frequency of deaths from cardiovascular causes (percentage)
Time frame: From enrollment to the end of treatment at 12 months
All-cause mortality
All-cause mortality rate (percentage)
Time frame: From enrollment to the end of treatment at 12 months
HF hospitalization (percentage)
Frequency of cases of HF hospitalization (percentage)
Time frame: From enrollment to the end of treatment at 12 months
Acute ischemic events (percentage)
The incidence of acute ischemic events requiring unplanned revascularization (percentage)
Time frame: From enrollment to the end of treatment at 12 months
Secondary composite endpoint (percentage)
The incidence of a secondary composite endpoint including cardiovascular (CV) death or nonfatal myocardial infarction (MI) and/or nonfatal stroke and/or unplanned revascularization and/or and HF hospitalization (percentage).
Time frame: From enrollment to the end of treatment at 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 12 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tomsk National Research Medical Center of the Russian Academy of Sciences